Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171 - PubMed (original) (raw)

Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171

W Binder et al. Eur J Neurosci. 1999 Jun.

Abstract

We have previously shown that kappa-opioids have antiarthritic properties. In this study, using two differently acting drugs (the peripherally selective kappa-agonist, asimadoline, and the NK1-antagonist, GR205171), we have examined possible roles of the neuropeptide substance P (SP) in the pathogenesis and maintenance of experimental arthritis in rats. The anti-inflammatory actions and the time dependence of these drugs were compared, and concentrations of SP determined in joint tissue. In untreated animals, SP levels in ankle joint tissue increased late in the disease (by day 21) but substantially lagged behind development of clinical disease. Prolonged (days 1-21 or days 12-18) but not early, short-term (days 1-3) treatment with the NK1-antagonist GR205171 (1 mg/kg/day i.p.) significantly attenuated joint damage; SP levels showed multiphasic dose dependence over the 21-day treatment. The data suggest that GR205171 antagonizes the action of SP by presynaptic as well as postsynaptic mechanisms. Treatment with asimadoline (5 mg/kg/day i.p. ) produced marked (and sustained) attenuation of the disease with all three time regimes. The effect of asimadoline on SP levels was time dependent: reduction of SP content after 3 days but an increase after 12 or 21 days treatment, paradoxically with clinical improvement in each case. Drug-induced changes in SP content could follow from changed release or synthesis from either neural or immune cells. The results suggest that both drugs have potential therapeutic value at different stages of inflammatory joint disease.

PubMed Disclaimer

Cited by

Evaluating the effect of ursodeoxycholic acid (UDCA) in comparison with dexamethasone and diclofenac in a rat model of rheumatoid arthritis.
Abduljaleel YR, Jwaid AH, Hussein AK. Abduljaleel YR, et al. J Med Life. 2023 Oct;16(10):1519-1526. doi: 10.25122/jml-2023-0107. J Med Life. 2023. PMID: 38313166 Free PMC article.
Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.
Taneja A, Della Pasqua O, Danhof M. Taneja A, et al. Eur J Clin Pharmacol. 2017 Oct;73(10):1219-1236. doi: 10.1007/s00228-017-2301-8. Epub 2017 Sep 11. Eur J Clin Pharmacol. 2017. PMID: 28894907 Free PMC article. Review.
Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.
Mangel AW, Hicks GA. Mangel AW, et al. Clin Exp Gastroenterol. 2012;5:1-10. doi: 10.2147/CEG.S23274. Epub 2012 Jan 12. Clin Exp Gastroenterol. 2012. PMID: 22346361 Free PMC article.
Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia.
Lawson KP, Nag S, Thompson AD, Mokha SS. Lawson KP, et al. Pain. 2010 Dec;151(3):806-815. doi: 10.1016/j.pain.2010.09.018. Pain. 2010. PMID: 20926192 Free PMC article.
Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation.
Camilleri M. Camilleri M. Neurogastroenterol Motil. 2008 Sep;20(9):971-9. doi: 10.1111/j.1365-2982.2008.01183.x. Neurogastroenterol Motil. 2008. PMID: 18715494 Free PMC article. Review.

Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171 - PubMed (original) (raw)